JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Lymph node transcriptomic profiles suggest susceptibility to bleomycin-induced pulmonary toxicity in classic hodgkin lymphoma

  • 0Department of Hematology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, DK-8200, Denmark. majaaner@rm.dk.
Scientific Reports +

|

August 18, 2025

|

August 18, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Predictive biomarkers for bleomycin-induced pulmonary toxicity (BPT) in classic Hodgkin lymphoma (CHL) are unknown. This study found immune and fibrotic signatures in diagnostic biopsies may predict BPT risk, enabling personalized CHL treatment.

Area Of Science

  • Oncology
  • Immunology
  • Pulmonology

Background

  • Bleomycin-induced pulmonary toxicity (BPT) is a significant concern in classic Hodgkin lymphoma (CHL) treatment, with undefined predictive biomarkers.
  • BPT affects approximately 10% of CHL patients and carries a 10-20% mortality rate, posing a clinical challenge.

Purpose Of The Study

  • To investigate the pre-therapeutic nodal tumor microenvironment in CHL patients to identify potential biomarkers for BPT development.
  • To correlate gene and protein expression profiles with BPT occurrence in CHL patients.

Main Methods

  • Gene expression profiling (GEP) of diagnostic lymph node biopsies from CHL patients who developed BPT (T-CHL) and those who did not (nT-CHL).
  • Differential protein expression analysis using immunohistochemistry (IHC) for key markers (MIF, pSTAT3, LILRB3, CD206) in an independent cohort.

Main Results

  • GEP revealed T-CHL samples were enriched in genes related to immune regulation, inflammation, fibrosis, and apoptosis signaling compared to nT-CHL.
  • IHC confirmed significantly higher expression of pSTAT3 and CD206, and lower expression of MIF and LILRB3 in T-CHL patients versus nT-CHL patients.
  • Immune and fibrotic signatures identified in diagnostic biopsies show potential as predictors of BPT risk.

Conclusions

  • Pre-therapeutic tumor microenvironment profiling, specifically immune and fibrotic signatures, may predict BPT risk in CHL patients.
  • Early identification of high-risk patients could facilitate personalized treatment strategies to mitigate BPT while maintaining treatment efficacy.
  • Tumor microenvironment characterization represents a promising approach for optimizing CHL patient care and reducing treatment-related toxicities.

Keywords: